E Fund Management Co. Ltd. Has $368,000 Position in Humana Inc. (NYSE:HUM)

E Fund Management Co. Ltd. increased its stake in shares of Humana Inc. (NYSE:HUM) by 94.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,450 shares of the insurance provider’s stock after buying an additional 703 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Humana were worth $368,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. FPC Investment Advisory Inc. acquired a new stake in Humana during the fourth quarter worth approximately $27,000. Centricity Wealth Management LLC acquired a new stake in Humana during the fourth quarter worth approximately $30,000. Ashton Thomas Securities LLC acquired a new stake in Humana during the third quarter worth approximately $31,000. Atwood & Palmer Inc. grew its position in Humana by 64.5% during the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider’s stock worth $39,000 after buying an additional 60 shares in the last quarter. Finally, Kestra Investment Management LLC acquired a new stake in Humana during the fourth quarter worth approximately $49,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Stock Down 2.2 %

Shares of NYSE:HUM opened at $259.86 on Friday. The firm has a market cap of $31.35 billion, a P/E ratio of 26.12, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46. The business has a fifty day simple moving average of $271.80 and a 200 day simple moving average of $283.63.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.36%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HUM has been the topic of a number of analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Piper Sandler upped their target price on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Truist Financial upped their target price on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research note on Monday, January 6th. Barclays upped their target price on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. cut their target price on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Twenty analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.